Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics), a US-based medical devices company, has appointed J. Melville Engle to the company as new board member. Engle has over 27 years experience in leading both large and small companies. He has raised money on Wall Street, launched hundreds of products, and has a broad management and financial background, including six years at Dey LP, where he was the firm's president and chief executive officer (CEO).
Subscribe to our email newsletter
Engle’s background also includes senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan, Inc.
“I’m very pleased that Mel has agreed to join our board,” said Chris J. Stern, company chairman and CEO. “He has the business acumen and experience in the pharmaceutical industry to help us develop and grow as we work to bring Oxycyte(R)-based products to the market. During his tenure at Dey, sales increased from $250 million to over $600 million. Our board and company will be stronger with his involvement.”
“I’m excited about the promise of Oxycyte and what I can see as the potential for this company. I’m looking forward to working with Chris and the other board members to help bring that potential to reality,” said Engle.